Arvinas shares gain as FDA approves breast cancer drug Veppanu

Investing.com -- Arvinas Inc. shares traded as much as 13% higher after resuming trading on Friday following the U.S. Food and Drug Administration's approval the company's drug VEPPANU.

The FDA approved VEPPANU (vepdegestrant) for treating adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer following disease progression after at least one line of endocrine therapy, according to a statement from Arvinas and Pfizer Inc.

The approval represents the first FDA-approved PROTAC, a type of heterobifunctional protein degrader therapy. The agency granted approval ahead of the June 5, 2026 PDUFA date.

You May Also Be Interested In

• NCCN adds Natera's Signatera to bladder cancer treatment guidelines
• Uxin reports Q1 2026 sales up 119%, eyes 100+ unit target
• Wells Fargo Downgrades Ross Stores, Inc. (ROST) to Equal Weight